Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Company Description
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China.
The company provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, fulvestrant, doxercalciferol, milrinone lactate, fondaparinux sodium, phenylephrine, gemcitabine, levoleucovorin, carboplatin, cytarabine, bleomycin, topotecan hydrochloride, bendamustine HCL, bortezomib, clofarabine, busulfan, dactinomycin, azacitidine, mycophenolate mofetil, tigecycline, glycopyrrolate, melphalan, daptomycin, decitabine, haloperidol decanoate, carmustine, bivalirudin, dexmedetomidine, and neostigmine methylsulfate injections.
It also offers isosulfan blue, succinylcholine chloride, furosemide, regadenoson, voriconazole, ganirelix acetate, eptifibatide, enoxaparin sodium, mitomycin, vancomycin, micafungin sodium, docetaxel, nelarabine, pemetrexed, rocuronium bromide, zoledronic acid, thiamine, fluorouracil, perixafor, thiotepa, pantoprazole sodium, glatiramer acetate, and bupivacaine hydrochloride injections.
The company was founded in 2000 and is based in Nanjing, China.
Country | China |
Founded | 2000 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 1,451 |
CEO | Tang Yongqun |
Contact Details
Address: No.16 Xuefu Road,High&New Tech Development Zone Nanjing, 210061 China | |
Phone | 86 25 8699 0701 |
Website | nkf-pharma.com |
Stock Details
Ticker Symbol | 603707 |
Exchange | Shanghai Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | CNY |
ISIN Number | CNE100002WP3 |
SIC Code | 2833 |
Key Executives
Name | Position |
---|---|
Wu Guiping | Deputy General Manager |
Tang Yongqun | GM and Chairman |
Xiaojie Qian | Financial Manager |
Dr. Huang Xiwei | Deputy GM, Secretary and Director |